• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
41,037 results

Regeneron Pharmaceuticals, Inc. v. Amgen Inc.

Docket 97878111, Trademark Trial and Appeal Board (Sept. 12, 2024)
Case TypeExtension of Time
TagsExtension, Time
MarksBIMTUVIQ
Defendant Amgen Inc.
Potential Opposer Regeneron Pharmaceuticals, Inc.
cite Cite Docket
Analyze

Novartis AG v. Amgen Inc.

Docket 91287397, Trademark Trial and Appeal Board (Sept. 28, 2023)
Case TypeOpposition
MarksPAVCUE, PAVBLU
DeadlineCONFERENCE, DISCOVERY, DISCLOSURE AND TRIAL SCHEDULE Time to Answer Deadline for Discovery Conference Discovery Opens Initial Disclosures Due Expert Disclosures Due Discovery Closes Plaintiff's Pretrial Disclosures Due Plaintiff's 30-day Trial Period Ends Defendant's Pretrial Disclosures Due Defendant's 30-day Trial Period Ends Plaintiff's Rebuttal Disclosures Due Plaintiff's 15-day Rebuttal Period Ends Plaintiff's Opening Brief Due Defendant's Brief Due Plaintiff's Reply Brief Due Request for Oral Hearing (optional) Due 11/7/2023 12/7/2023 12/7/2023 1/6/2024 5/5/2024 6/4/2024 7/19/2024 9/2/2024 9/17/2024 11/1/2024 11/16/2024 12/16/2024 2/14/2025 3/16/2025 3/31/2025 4/10/2025
Applicant Amgen Inc.
Opposer Novartis AG
cite Cite Docket
Analyze

Novartis AG v. Amgen Inc.

Docket 97353493, Trademark Trial and Appeal Board (Apr. 27, 2023)
Case TypeExtension of Time
TagsExtension, Time
MarksPAVBLU
Defendant Amgen Inc.
Potential Opposer Novartis AG
cite Cite Docket
Analyze

Teva Pharmaceuticals USA, Inc. v. Amgen Inc.

Docket 91266974, Trademark Trial and Appeal Board (Jan. 11, 2021)
Case TypeOpposition
MarksWELTRUZA, WELKINZA
Applicant Amgen Inc.
Opposer Teva Pharmaceuticals USA, Inc.
cite Cite Docket
Analyze

Teva Pharmaceuticals USA, Inc. v. Amgen Inc.

Docket 88903727, Trademark Trial and Appeal Board (Aug. 6, 2020)
Case TypeExtension of Time
TagsExtension, Time
MarksWELKINZA
Defendant Amgen Inc.
Potential Opposer Teva Pharmaceuticals USA, Inc.
cite Cite Docket
Analyze

No. 4 - Ext Granted

Document Regeneron Pharmaceuticals, Inc. v. Amgen Inc., 97878111, No. 4 (T.T.A.B. Oct. 8, 2024)
The request to extend time to oppose is granted until 12/11/2024 on behalf of potential opposer Regeneron Pharmaceuticals, Inc..
cite Cite Document
Analyze

No. 2 - Ext Granted

Document Regeneron Pharmaceuticals, Inc. v. Amgen Inc., 97878111, No. 2 (T.T.A.B. Sep. 12, 2024)
The request to extend time to oppose is granted until 10/12/2024 on behalf of potential opposer Regeneron Pharmaceuticals, Inc..
cite Cite Document
Analyze

MARITIDE

Docket 98404415, Trademark (Feb. 13, 2024)
ClassResearch and development of pharmaceutical preparations; research and development of pharmaceutical preparations in the field of metabolic diseases, namely weight management and diabetes; medical and scientific research information in clinical trials in the field of metabolic diseases, namely weight management and diabetes; providing websites featuring medical and scientific research information about the diagnostic, prophylactic and therapeutic properties of pharmaceuticals in the field of metabolic diseases, namely weight management and diabetes; providing websites featuring medical and scientific research information about pharmaceuticals preparations in the field of metabolic diseases, namely weight management and diabetes; providing websites that features non-downloadable computer software that enables users to access, manage, update and display electronic databases in the field of metabolic diseases, namely weight management and diabetes; 100; 101
MarksMARITIDE
Owner at Publication Amgen Inc.
cite Cite Docket
Analyze
1 2 3 4 5 ... >>